169 filings
6-K
MDNAF
Medicenna Therapeutics Corp.
25 Apr 24
Medicenna Announces Oral Presentation of MDNA11 Data from the Phase 1/2 ABILITY-1 Study at the 2024 ASCO Annual Meeting
2:00pm
AW
MDNAF
Medicenna Therapeutics Corp.
22 Apr 24
Withdrawal of amendment
4:40pm
S-8 POS
MDNAF
Medicenna Therapeutics Corp.
16 Apr 24
Registration of securities for employees (post-effective amendment)
5:05pm
F-3/A
MDNAF
Medicenna Therapeutics Corp.
16 Apr 24
Shelf registration (foreign) (amended)
5:05pm
F-10POS
MDNAF
Medicenna Therapeutics Corp.
16 Apr 24
Automatic registration of securities (post-effective amendment, Canada)
5:04pm
6-K
sfzwu6rwy
9 Apr 24
Current report (foreign)
8:44pm
6-K
d54wc32 kpngc
9 Apr 24
Current report (foreign)
2:05pm
6-K
mv3zkuuv6308
4 Apr 24
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
2:00pm
6-K
vrkpx7 ay37j
6 Mar 24
Medicenna to Provide Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming American Association for Cancer Research Annual Meeting
11:00am
SC 13G/A
amc5yjylh wq
21 Feb 24
Medicenna Therapeutics / Merchant Fahar ownership change
8:26pm
6-K
mizjiy72fxmrn3bu277
14 Feb 24
Interim condensed consolidated financial statements of
7:30am
6-K
xaiedvpb
13 Feb 24
Current report (foreign)
10:30am
SC 13G/A
1vx8kj07cb7n2w
7 Feb 24
Medicenna Therapeutics / HIRSCHMAN ORIN ownership change
6:55pm
6-K
fkqe 16yemcv9
24 Jan 24
Notice of Change of Auditor
4:00pm
6-K
ziuu2i451 84
12 Jan 24
Medicenna Announces Appointment of New Auditor
7:15pm
6-K
lkg636
9 Jan 24
Medicenna Commences Enrollment in the ABILITY-1 Study Combining MDNA11 with Pembrolizumab
10:33am
6-K
cj7d qi62kabklq3xra
5 Jan 24
Notice of Change of Auditor
9:06am
6-K
wh5pkl bcsrqbw6pe
22 Dec 23
Current report (foreign)
2:13pm
6-K
w9bq36z
21 Dec 23
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAF
7:31pm
6-K
d8hzddz67n8grry406f
21 Nov 23
Current report (foreign)
10:39am